title: Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting.
authors.affiliation: Cardiac Unit, University of Vermont College of Medicine, 111 Colchester Avenue, Burlington, VT 05401, USA.
authors.forename: Atul
authors.initials: A
authors.lastname: Aggarwal
authors.forename: David J
authors.initials: DJ
authors.lastname: Schneider
authors.forename: Edward F
authors.initials: EF
authors.lastname: Terrien
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Terrien
authors.forename: Burton E
authors.initials: BE
authors.lastname: Sobel
authors.forename: Harold L
authors.initials: HL
authors.lastname: Dauerman
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001167:Arteritis / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000187:drug effects*; D023921:Coronary Stenosis / Q000628:therapy*; D003331:Coronary Vessels / Q000378:metabolism / Q000601:surgery; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011446:Prospective Studies; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D015607:Stents / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D015415:Biomarkers; D007140:Immunoglobulin Fab Fragments; D015850:Interleukin-6; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D017472:Receptors, Interleukin-1; D002097:C-Reactive Protein; D000077542:Eptifibatide; D000077284:Abciximab